Letter ·
NAMD Warns Against Broadly Defining Pharmaceutical Value-Based Purchasing in Draft PAVE Act
NAMD wrote to Congress expressing concern with draft legislation that would broadly define pharmaceutical value-based purchasing in a manner that could undermine the Medicaid drug rebate program.
In 2019, Senators Cassidy and Warner introduced the Patient Affordability Value and Efficiency Act, which sought to broadly define pharmaceutical value-based purchasing. In this letter, NAMD warns that such a broad definition would negatively impact fundamental aspects of the Medicaid drug rebate program and increase Medicaid pharmacy benefit spending.
Related resources
Prescription Drug Spending: What’s Coming Next for Medicaid and How Can States Prepare?
NAMD Comments on Medicare’s Proposed Coverage Determination for Alzheimer’s Drug
Stay Informed
Drop us your email and we’ll keep you up-to-date on Medicaid issues.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.